Organisation
Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven)
Division
The Lab of Molecular Oncology and Angiogenesis aims to shed light on the genetic and molecular mechanisms that regulate vessel shape remodeling and endothelial cell fate, with the overall aim of defining alternative therapeutic opportunities to improve anti-cancer therapy, as well as therapeutic angiogenesis for revascularization of ischemic tissues.
Current researchers
1 - 7 of 7 results
- Max Mazzone (Responsible)
- Emanuele Berardi (Member)
- Marie-Pauline Orban (Member)
- Carla Riera Domingo (Member)
- Silvia Rivis (Member)
- Tommaso Scolaro (Member)
- Shikang Zhao (Member)
Projects
1 - 10 of 68
- Targeting the DNA methylation profile of cytotoxic T cells to overcome immunotherapy resistance of pancreatic cancerFrom5 Mar 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding glutamate metabolism in the tumor microenvironment to tackle Immune Checkpoint Blockade (ICB) resistanceFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Role of SLC1A3 in tumor-associated macrophages during immunotherapy resistance onset in breast cancerFrom1 Oct 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Targeting the CDA/P2Y6 axis to overcome immunosuppression and favor response to immune checkpoint inhibitors in pancreatic cancerFrom1 Jul 2023 → TodayFunding: Other federal public and semi-governmental institutions
- Tackling tumor immunosuppression by reprograming eicosanoid metabolism and signaling in the tumor microenvironmentFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Tackling SLC1A3 in tumor-associated macrophages to overcome anti-PD1 immunotherapy resistance in breast cancerFrom31 Oct 2022 → TodayFunding: FWO Strategic Basic Research Grant
- LipoMacs: functional Lipidomics to unlock Macrophage-mediated therapyFrom1 Oct 2022 → TodayFunding: FWO Strategic Basic Research (SBO)
- BD Imaging Cell Sorter – BD Cell View TechnologyTMFrom24 Jun 2022 → TodayFunding: Other federal scientific institutions
- Tricking tumor immunosuppression: RNA epigenetics as novel target to improve cancer immunotherapyFrom1 Jan 2022 → TodayFunding: FWO EOS
- Duchenne muscular dystrophy.From1 Jan 2022 → 31 Dec 2022Funding: Nonprofit institution or equivalents
Publications
291 - 300 of 314
- Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)(2021)
Authors: Eric Van Cutsem, Hans Prenen
- Oesophageal cancer(2016)
Authors: Peter Dirix, Karin Haustermans, Eric Van Cutsem, Xavier Sagaert, Christophe Deroose, Philippe Nafteux, Hans Prenen, Toni Lerut
Pages: 365 - 387 - An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates(2020)
Authors: Katerina Rohlenova, Federico Taverna, Lucas Treps, Vincent Geldhof, Laura De Rooij, Liliana Sokol, Junbin Qian, Laure-Anne Teuwen, Bram Boeckx, Els Wauters, et al.
Pages: 21 - + - Risicofactoren voor het ontwikkelen van een barrettslokdarm en kwaadaardige ontaarding. Zijn er preventieve maatregelen?(2011)
Authors: Hans Prenen
Pages: 907 - 910 - Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer(2014)
Authors: Eric Van Cutsem, Hans Prenen
Pages: 4240 - 4250 - RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment(2019)
Authors: Peter A van Dam, Yannick Verhoeven, Xuan B Trinh, An Wouters, Filip Lardon, Hans Prenen, Evelien Smits, Marcella Baldewijns, Martin Lammens
Pages: 85 - 91 - PHASE I/II STUDY OF FOLFIRI PLUS THE MEK1/2 INHIBITOR PIMASERTIB (MSC1936369B) AS SECOND-LINE TREATMENT FOR KRAS MUTATED METASTATIC COLORECTAL CANCER(2012)
Authors: Teresa Macarulla, Josep Tabernero, Andres Cervantes, Susana Rosello, Eric Van Cutsem, Sabine Tejpar, Hans Prenen, Erika Martinelli, Teresa Troiani, Fank Campana, et al.
Pages: 27 - 27 - Analysis of the formalin-fixed paraffin-embedded tissue proteome: pitfalls, challenges, and future prospectives(2013)
Authors: Evelyne Maes, Valerie Broeckx, Xavier Sagaert, Hans Prenen, Bart Landuyt, Liliane Schoofs
Pages: 205 - 218 - Iron deficiency in gastrointestinal oncology(2015)
Authors: Hans Prenen
Pages: 19 - 24 - Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Kohne Prognostic Category and BRAF Mutation Status(2018)
Authors: Hans Prenen
Pages: 50 - +